While Cytokinetics Inc has overperformed by 2.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CYTK fell by -42.81%, with highs and lows ranging from $84.92 to $44.49, whereas the simple moving average fell by -12.97% in the last 200 days.
On January 22, 2025, Stifel started tracking Cytokinetics Inc (NASDAQ: CYTK) recommending Buy. A report published by RBC Capital Mkts on November 08, 2024, Initiated its previous ‘Outperform’ rating for CYTK. Goldman also Downgraded CYTK shares as ‘Neutral’, setting a target price of $60 on the company’s shares in a report dated August 13, 2024. UBS January 24, 2024d the rating to Neutral on January 24, 2024, and set its price target from $61 to $92. Morgan Stanley January 05, 2024d its ‘Overweight’ rating to ‘Equal-Weight’ for CYTK, as published in its report on January 05, 2024. Goldman’s report from November 09, 2023 suggests a price prediction of $50 for CYTK shares, giving the stock a ‘Buy’ rating. B. Riley Securities also rated the stock as ‘Buy’.
Analysis of Cytokinetics Inc (CYTK)
Further, the quarter-over-quarter increase in sales is 22.49%, showing a positive trend in the upcoming months.
Cytokinetics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. Taking into account the quick ratio of the company, currently set at 9.28, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and CYTK has an average volume of 1.20M. On a monthly basis, the volatility of the stock is set at 3.78%, whereas on a weekly basis, it is put at 3.71%, with a gain of 2.11% over the past seven days. Furthermore, long-term investors anticipate a median target price of $81.83, showing growth from the present price of $47.86, which can serve as yet another indication of whether CYTK is worth investing in or should be passed over.
How Do You Analyze Cytokinetics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.77%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 113.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CYTK shares are owned by institutional investors to the tune of 113.05% at present.
